Biopharmas raising money in public or private financings, including: Anvesana, Apollo, Aptose, Hanmi, Imvax, Jiangsu Nhwa, Medexus, Nimbus, Nurexone, Rejuvenation, Tentarix, Trevena.

Biopharmas in Asia-Pacific raising money in public or private financings: Epigenic, Innovac.

Star Therapeutics Inc. brought on board six new investors in its oversubscribed $90 million series C round, raising the company’s total funding to more than $190 million since its founding in 2018 to advance in-house drug discovery efforts via formation of portfolio companies. Since emerging from stealth in early 2022, Star has launched two aptly named companies, Electra Therapeutics Inc. and Vega Therapeutics Inc., with plans to unveil additional ventures arising from its antibody discovery efforts.

Biopharmas raising money in public or private financings, including: Betterlife, Daré, Fimmcyte, HHC Medical, Olema, Solid.

Biopharmas raising money in public or private financings, including: Alligator, Alpha Cognition, Clock Bio, Innovac.

Med-tech firms raising money in public or private financings, including: Nanovibronix, Royal Philips.

Biopharmas raising money in public or private financings, including: Inventiva.

“Sometimes the market gets ahead of the science,” said Dennis Purcell, founder of Aisling Capital, pointing to the way backers of genomics firms “went nuts” in the early 2000s. “I think we’re in a position today where the science is ahead of where the market is.” The remarks by venture capital (VC) expert Purcell came during a virtual salon hosted Aug. 30 by Demy-Colton and titled “VC Trends in Healthcare Investing: Current Pulse Check.” Panelists acknowledged the currently unfavorable financing environment but sounded upbeat about the industry’s path forward.